Furthermore, using CB-839 as a pharmacological tool, we demonstrated that inhibition of GLS leads to a decrease in mTOR activity and an increase in the ATF4 stress response pathway only in responder breast cancer cell lines, suggesting that these molecular changes may be utilized as predictive PD/efficacy biomarkers for GLS inhibitor treatment. This evidence concerns the gene GLS and breast carcinoma.